Effect of age on plasma propranolol levels [letter]

Schneider, R.; Bishop, H.; Yates, R A; Quarterman, CP; Kendall, M. J.

doi:10.1111/j.1365-2125.1980.tb01736.x

Cited by 38 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pindolol (Hitzenberger et al, 1982) atenolol +1 +1 (Rigby et al, 1985) and acebutolol (Roux et al, 1983). However, other comparisons of the kinetics in young and old healthy subjects have a failed to reveal differences for propranolol (Schneider et al, 1980;Rigby et al, 1985), or°m etoprolol (Quarterman et al, 1981;Rigby et X .o * 2 al., 1985). The reason for the differences found b .. in the present study may therefore lie in the i fact that the elderly subjects studied were patients often on drug therapy for other disease processes rather than healthy old persons in the community, i.e.…”

Section: A°tmentioning

confidence: 98%

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

Bradbrook¹,

Babiker²,

Crome³

et al. 1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

Oxprenolol in an Oros 8/130 sustained release osmotic pump system (equivalent to 120 mg oxprenolol hydrochloride in a conventional formulation and releasing 8 mg h‐1) was given to eight normal young subjects (mean age 23 years) and eight elderly hypertensive patients (mean age 77 years). The plasma concentration‐time profiles of oxprenolol were determined over 32 h using gas liquid chromatography after the initial dose and following seven doses. The elderly patients had a significantly higher AUC and maximum plasma oxprenolol concentration following both the first and final doses studied. It is unlikely that this difference is due to a prolonged absorption phase in the elderly patients. Reduced drug clearance seems the most probable explanation.

show abstract

Section: A°tmentioning

confidence: 98%

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

Bradbrook¹,

Babiker²,

Crome³

et al. 1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…However, luded following thyroidectomy (two due to Schneider et al (1980) following single oral doses of te compliance and a third patient stopped 40 and 80 mg of propranolol did not find an age related reduction in the clearance of propranolol in eady state had been achieved during chronic non-smoking healthy subjects. They suggested that t was supported by the finding that the the use of sick elderly subjects in the former study Iropranolol concentration at the beginning may explain the different findings.…”

Section: Introduction Methodsmentioning

confidence: 99%

The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.

Feely¹,

Crooks²,

Stevenson³

1981

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Plasma propranolol steady state concentration (Css) was determined during chronic dosage (160 mg/day) in 22 hyperthyroid patients (aged 16-75 years, 11 smokers, 11 non-smokers) and again following treatment when euthyroid. 2 There was a positive correlation between plasma propranolol Css and age in patients both when hyperthyroid (r = 0.74, P< 0.01) and when euthyroid (r = 0.58, P < 0.05). 3 Plasma propranolol Css in hyperthyroid patients were lower (P < 0.05) in smokers than in non-smokers. 4 Following correction of hyperthyroidism there was a significant increase (P < 0.01) in both the plasma propranolol Css and degree of plasma protein binding of propranolol. 5Hyperthyroidism and smoking are known to increase the rate of drug metabolism and it is suggested that these variables may give rise to or accentuate an age related reduction in propranolol clearance.

show abstract

“…There is, however, some evidence that these drugs are less effective in older patients (Schocken & Roth, 1977) although this has not been formally investigated. The pharmacokinetics of propranolol and metoprolol (Schneider et al, 1980;Schneck et al, 1980;Quarterman et al, 1981) are probably little altered in fit elderly people, but this does not apply to hospitalized patients (Castleden & George, 1979). Water soluble drugs such as atenolol which are mainly excreted by the kidney may reach much higher blood levels in the elderly, and should, in theory, be given in reduced dosage (Kurch & Gorg, 1982) although, in practice, higher doses are tolerated (O'Callaghan et al, 1983).…”

Section: P-adrenergic Blockersmentioning

confidence: 99%